Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis.
Hepatitis B virus
Sub-Saharan Africa
antiviral treatment
cirrhosis
liver fibrosis
systematic review
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
26
10
2020
received:
19
08
2020
accepted:
17
11
2020
pubmed:
22
11
2020
medline:
22
6
2021
entrez:
21
11
2020
Statut:
ppublish
Résumé
Chronic hepatitis B virus (HBV) infection accounts for 30%-50% of cirrhosis related deaths in sub-Saharan Africa (SSA). Since HBV-related cirrhosis is an indication for immediate antiviral therapy and cancer surveillance, we aimed to estimate the prevalence of cirrhosis among treatment-naïve patients with chronic HBV infection in SSA. We performed a systematic review of published articles which evaluated liver fibrosis stage among treatment-naïve HBV-infected individuals who presented to care in SSA. Our primary outcome was the prevalence of cirrhosis in HBsAg-positive persons, which was estimated using random-effects meta-analysis. Risk factors for cirrhosis were explored using subgroup-analyses and multivariable meta-regression. Of 2129 articles identified, 17 met our eligibility criteria. The studies described 22 cohorts from 13 countries, including 13 cohorts (3204 patients) with chronic HBV mono-infection and nine cohorts (688 patients) with HIV/HBV-coinfection. Liver fibrosis was assessed using transient elastography (10 cohorts), APRI score (11 cohorts), and Fibrotest (one cohort). The pooled prevalence of cirrhosis was 4.1% (95% confidence interval [CI] 2.6-6.4) among studies from primary care facilities or general population, compared to 12.7% (95% CI 8.6-18.3) in studies performed in referral or tertiary care facilities (adjusted odds ratio 0.29, 95% CI 0.15-0.56). We found no association between cirrhosis and age, gender, fibrosis test used or HIV-coinfection. Depending on the setting, between 4% and 13% of HBV-infected individuals in SSA have cirrhosis and need immediate antiviral therapy. These estimates should be considered when planning HBV treatment strategies and resource allocation.
Sections du résumé
BACKGROUND & AIMS
Chronic hepatitis B virus (HBV) infection accounts for 30%-50% of cirrhosis related deaths in sub-Saharan Africa (SSA). Since HBV-related cirrhosis is an indication for immediate antiviral therapy and cancer surveillance, we aimed to estimate the prevalence of cirrhosis among treatment-naïve patients with chronic HBV infection in SSA.
METHODS
We performed a systematic review of published articles which evaluated liver fibrosis stage among treatment-naïve HBV-infected individuals who presented to care in SSA. Our primary outcome was the prevalence of cirrhosis in HBsAg-positive persons, which was estimated using random-effects meta-analysis. Risk factors for cirrhosis were explored using subgroup-analyses and multivariable meta-regression.
RESULTS
Of 2129 articles identified, 17 met our eligibility criteria. The studies described 22 cohorts from 13 countries, including 13 cohorts (3204 patients) with chronic HBV mono-infection and nine cohorts (688 patients) with HIV/HBV-coinfection. Liver fibrosis was assessed using transient elastography (10 cohorts), APRI score (11 cohorts), and Fibrotest (one cohort). The pooled prevalence of cirrhosis was 4.1% (95% confidence interval [CI] 2.6-6.4) among studies from primary care facilities or general population, compared to 12.7% (95% CI 8.6-18.3) in studies performed in referral or tertiary care facilities (adjusted odds ratio 0.29, 95% CI 0.15-0.56). We found no association between cirrhosis and age, gender, fibrosis test used or HIV-coinfection.
CONCLUSIONS
Depending on the setting, between 4% and 13% of HBV-infected individuals in SSA have cirrhosis and need immediate antiviral therapy. These estimates should be considered when planning HBV treatment strategies and resource allocation.
Identifiants
pubmed: 33220137
doi: 10.1111/liv.14744
pmc: PMC8048614
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
710-719Informations de copyright
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Int J Health Policy Manag. 2014 Aug 13;3(3):123-8
pubmed: 25197676
Evid Based Ment Health. 2019 Nov;22(4):153-160
pubmed: 31563865
Int J STD AIDS. 2013 Jun;24(6):461-7
pubmed: 23970749
Liver Int. 2021 Apr;41(4):710-719
pubmed: 33220137
Lancet. 2013 Feb 9;381(9865):468-75
pubmed: 23234725
Clin Infect Dis. 2017 May 15;64(10):1343-1349
pubmed: 28158504
Hepatology. 2017 Nov;66(5):1444-1453
pubmed: 28622419
BMC Res Notes. 2019 Jul 31;12(1):466
pubmed: 31366401
J Hepatol. 2019 Jun;70(6):1065-1071
pubmed: 30929749
PLoS One. 2020 Jan 13;15(1):e0227041
pubmed: 31929556
Clin Infect Dis. 2013 Dec;57(12):e189-92
pubmed: 24014732
World J Hepatol. 2018 Sep 27;10(9):622-628
pubmed: 30310540
Hepatology. 2013 Nov;58(5):1537-47
pubmed: 23389810
Gastroenterology. 2006 Mar;130(3):678-86
pubmed: 16530509
Liver Int. 2017 Aug;37(8):1116-1121
pubmed: 28561454
PLoS One. 2017 Jul 31;12(7):e0181836
pubmed: 28759595
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266
pubmed: 31981519
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):298-302
pubmed: 29016448
J Hepatol. 2016 Apr;64(4):773-80
pubmed: 26626497
Gut. 2016 Dec;65(12):2007-2016
pubmed: 26185161
J Hepatol. 2006;44(1 Suppl):S65-70
pubmed: 16338021
J Trop Med. 2017;2017:5629130
pubmed: 28828009
J Hepatol. 2019 Aug;71(2):274-280
pubmed: 30965070
Trans R Soc Trop Med Hyg. 2019 Jan 1;113(1):11-17
pubmed: 30452730
BMC Infect Dis. 2015 Apr 11;15:180
pubmed: 25886382
Open Forum Infect Dis. 2016 Jul 29;3(3):ofw162
pubmed: 27704017
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
PLoS One. 2012;7(10):e45750
pubmed: 23049685
Lancet Glob Health. 2016 Aug;4(8):e559-67
pubmed: 27443781
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):900-909
pubmed: 29132759